Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
36
PROK Quote, Financials, Valuation and Earnings
Last price:
$1.92
Seasonality move
:
5.69%
Day range:
$1.68 - $1.92
52-week range:
$0.46 - $7.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
284.65x
P/B ratio:
--
Volume:
1.1M
Avg. volume:
749.1K
1-year change:
126.27%
Market cap:
$295.1M
Revenue:
$893K
EPS (TTM):
-$0.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PROK
ProKidney Corp.
|
$100.3K | -$0.14 | -56.41% | -7.94% | $6.25 |
|
AQST
Aquestive Therapeutics, Inc.
|
$10.9M | -$0.13 | 24.95% | -45.86% | $8.89 |
|
KRRO
Korro Bio, Inc.
|
$438.1K | -$1.98 | -82.82% | -20.47% | $20.00 |
|
NAGE
Niagen Bioscience, Inc.
|
$30.4M | $0.06 | -0.82% | 23.36% | $13.60 |
|
NAUT
Nautilus Biotechnology, Inc.
|
-- | -$0.15 | -- | -- | $4.00 |
|
NMRA
Neumora Therapeutics, Inc.
|
-- | -$0.31 | -- | -23.34% | $8.91 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PROK
ProKidney Corp.
|
$1.90 | $6.25 | $295.1M | -- | $0.00 | 0% | 284.65x |
|
AQST
Aquestive Therapeutics, Inc.
|
$4.13 | $8.89 | $504.7M | -- | $0.00 | 0% | 9.92x |
|
KRRO
Korro Bio, Inc.
|
$14.00 | $20.00 | $221.7M | -- | $0.00 | 0% | 22.59x |
|
NAGE
Niagen Bioscience, Inc.
|
$4.38 | $13.60 | $350.8M | 21.44x | $0.00 | 0% | 2.88x |
|
NAUT
Nautilus Biotechnology, Inc.
|
$3.31 | $4.00 | $412.7M | -- | $0.00 | 0% | -- |
|
NMRA
Neumora Therapeutics, Inc.
|
$2.00 | $8.91 | $348.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PROK
ProKidney Corp.
|
-0.4% | 3.062 | 0.25% | 8.78x |
|
AQST
Aquestive Therapeutics, Inc.
|
134.43% | 0.879 | 16.67% | 2.71x |
|
KRRO
Korro Bio, Inc.
|
45.81% | 2.496 | 57.65% | 6.46x |
|
NAGE
Niagen Bioscience, Inc.
|
3.55% | 3.664 | 0.56% | 3.75x |
|
NAUT
Nautilus Biotechnology, Inc.
|
16.05% | -3.324 | 12.17% | 13.00x |
|
NMRA
Neumora Therapeutics, Inc.
|
13.19% | 4.059 | 6.81% | 6.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PROK
ProKidney Corp.
|
-$1.2M | -$45.4M | -43.33% | -43.81% | -20164.89% | -$38.3M |
|
AQST
Aquestive Therapeutics, Inc.
|
$7.2M | -$28.8M | -104.31% | -- | -221.58% | -$8.6M |
|
KRRO
Korro Bio, Inc.
|
$643K | -$15.9M | -74.43% | -103.78% | -1229.33% | -$17.8M |
|
NAGE
Niagen Bioscience, Inc.
|
$21.7M | $2.1M | 26.48% | 27.78% | 6.22% | $523K |
|
NAUT
Nautilus Biotechnology, Inc.
|
-$1.6M | -$15.4M | -27.95% | -32.41% | -- | -$12.6M |
|
NMRA
Neumora Therapeutics, Inc.
|
-$23K | -$52.7M | -98.72% | -102.63% | -- | -$46.6M |
ProKidney Corp. vs. Competitors
-
Which has Higher Returns PROK or AQST?
Aquestive Therapeutics, Inc. has a net margin of -18156.44% compared to ProKidney Corp.'s net margin of -244.8%. ProKidney Corp.'s return on equity of -43.81% beat Aquestive Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PROKProKidney Corp.-544% -$0.14 $304.8M AQSTAquestive Therapeutics, Inc.55.16% -$0.26 $97.8M -
What do Analysts Say About PROK or AQST?
ProKidney Corp. has a consensus price target of $6.25, signalling upside risk potential of 228.95%. On the other hand Aquestive Therapeutics, Inc. has an analysts' consensus of $8.89 which suggests that it could grow by 115.23%. Given that ProKidney Corp. has higher upside potential than Aquestive Therapeutics, Inc., analysts believe ProKidney Corp. is more attractive than Aquestive Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PROKProKidney Corp.4 2 0 AQSTAquestive Therapeutics, Inc.7 0 0 -
Is PROK or AQST More Risky?
ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aquestive Therapeutics, Inc. has a beta of 1.541, suggesting its more volatile than the S&P 500 by 54.126%.
-
Which is a Better Dividend Stock PROK or AQST?
ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aquestive Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. Aquestive Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PROK or AQST?
ProKidney Corp. quarterly revenues are $225K, which are smaller than Aquestive Therapeutics, Inc. quarterly revenues of $13M. ProKidney Corp.'s net income of -$40.9M is lower than Aquestive Therapeutics, Inc.'s net income of -$31.9M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while Aquestive Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 284.65x versus 9.92x for Aquestive Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PROKProKidney Corp.284.65x -- $225K -$40.9M AQSTAquestive Therapeutics, Inc.9.92x -- $13M -$31.9M
-
Which has Higher Returns PROK or KRRO?
Korro Bio, Inc. has a net margin of -18156.44% compared to ProKidney Corp.'s net margin of -3873.22%. ProKidney Corp.'s return on equity of -43.81% beat Korro Bio, Inc.'s return on equity of -103.78%.
Company Gross Margin Earnings Per Share Invested Capital PROKProKidney Corp.-544% -$0.14 $304.8M KRROKorro Bio, Inc.49.77% -$5.32 $94.9M -
What do Analysts Say About PROK or KRRO?
ProKidney Corp. has a consensus price target of $6.25, signalling upside risk potential of 228.95%. On the other hand Korro Bio, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 42.86%. Given that ProKidney Corp. has higher upside potential than Korro Bio, Inc., analysts believe ProKidney Corp. is more attractive than Korro Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PROKProKidney Corp.4 2 0 KRROKorro Bio, Inc.5 2 0 -
Is PROK or KRRO More Risky?
ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Korro Bio, Inc. has a beta of 3.205, suggesting its more volatile than the S&P 500 by 220.462%.
-
Which is a Better Dividend Stock PROK or KRRO?
ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Korro Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. Korro Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PROK or KRRO?
ProKidney Corp. quarterly revenues are $225K, which are smaller than Korro Bio, Inc. quarterly revenues of $1.3M. ProKidney Corp.'s net income of -$40.9M is higher than Korro Bio, Inc.'s net income of -$50M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while Korro Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 284.65x versus 22.59x for Korro Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PROKProKidney Corp.284.65x -- $225K -$40.9M KRROKorro Bio, Inc.22.59x -- $1.3M -$50M
-
Which has Higher Returns PROK or NAGE?
Niagen Bioscience, Inc. has a net margin of -18156.44% compared to ProKidney Corp.'s net margin of 12.21%. ProKidney Corp.'s return on equity of -43.81% beat Niagen Bioscience, Inc.'s return on equity of 27.78%.
Company Gross Margin Earnings Per Share Invested Capital PROKProKidney Corp.-544% -$0.14 $304.8M NAGENiagen Bioscience, Inc.64.14% $0.05 $79.4M -
What do Analysts Say About PROK or NAGE?
ProKidney Corp. has a consensus price target of $6.25, signalling upside risk potential of 228.95%. On the other hand Niagen Bioscience, Inc. has an analysts' consensus of $13.60 which suggests that it could grow by 210.5%. Given that ProKidney Corp. has higher upside potential than Niagen Bioscience, Inc., analysts believe ProKidney Corp. is more attractive than Niagen Bioscience, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PROKProKidney Corp.4 2 0 NAGENiagen Bioscience, Inc.5 0 0 -
Is PROK or NAGE More Risky?
ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Niagen Bioscience, Inc. has a beta of 2.235, suggesting its more volatile than the S&P 500 by 123.522%.
-
Which is a Better Dividend Stock PROK or NAGE?
ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Niagen Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. Niagen Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PROK or NAGE?
ProKidney Corp. quarterly revenues are $225K, which are smaller than Niagen Bioscience, Inc. quarterly revenues of $33.8M. ProKidney Corp.'s net income of -$40.9M is lower than Niagen Bioscience, Inc.'s net income of $4.1M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while Niagen Bioscience, Inc.'s PE ratio is 21.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 284.65x versus 2.88x for Niagen Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PROKProKidney Corp.284.65x -- $225K -$40.9M NAGENiagen Bioscience, Inc.2.88x 21.44x $33.8M $4.1M
-
Which has Higher Returns PROK or NAUT?
Nautilus Biotechnology, Inc. has a net margin of -18156.44% compared to ProKidney Corp.'s net margin of --. ProKidney Corp.'s return on equity of -43.81% beat Nautilus Biotechnology, Inc.'s return on equity of -32.41%.
Company Gross Margin Earnings Per Share Invested Capital PROKProKidney Corp.-544% -$0.14 $304.8M NAUTNautilus Biotechnology, Inc.-- -$0.11 $187M -
What do Analysts Say About PROK or NAUT?
ProKidney Corp. has a consensus price target of $6.25, signalling upside risk potential of 228.95%. On the other hand Nautilus Biotechnology, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 21.03%. Given that ProKidney Corp. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe ProKidney Corp. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PROKProKidney Corp.4 2 0 NAUTNautilus Biotechnology, Inc.2 0 0 -
Is PROK or NAUT More Risky?
ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nautilus Biotechnology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PROK or NAUT?
ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nautilus Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. Nautilus Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PROK or NAUT?
ProKidney Corp. quarterly revenues are $225K, which are larger than Nautilus Biotechnology, Inc. quarterly revenues of --. ProKidney Corp.'s net income of -$40.9M is lower than Nautilus Biotechnology, Inc.'s net income of -$13.8M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while Nautilus Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 284.65x versus -- for Nautilus Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PROKProKidney Corp.284.65x -- $225K -$40.9M NAUTNautilus Biotechnology, Inc.-- -- -- -$13.8M
-
Which has Higher Returns PROK or NMRA?
Neumora Therapeutics, Inc. has a net margin of -18156.44% compared to ProKidney Corp.'s net margin of --. ProKidney Corp.'s return on equity of -43.81% beat Neumora Therapeutics, Inc.'s return on equity of -102.63%.
Company Gross Margin Earnings Per Share Invested Capital PROKProKidney Corp.-544% -$0.14 $304.8M NMRANeumora Therapeutics, Inc.-- -$0.35 $152.2M -
What do Analysts Say About PROK or NMRA?
ProKidney Corp. has a consensus price target of $6.25, signalling upside risk potential of 228.95%. On the other hand Neumora Therapeutics, Inc. has an analysts' consensus of $8.91 which suggests that it could grow by 345.38%. Given that Neumora Therapeutics, Inc. has higher upside potential than ProKidney Corp., analysts believe Neumora Therapeutics, Inc. is more attractive than ProKidney Corp..
Company Buy Ratings Hold Ratings Sell Ratings PROKProKidney Corp.4 2 0 NMRANeumora Therapeutics, Inc.5 1 0 -
Is PROK or NMRA More Risky?
ProKidney Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neumora Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PROK or NMRA?
ProKidney Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neumora Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProKidney Corp. pays -- of its earnings as a dividend. Neumora Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PROK or NMRA?
ProKidney Corp. quarterly revenues are $225K, which are larger than Neumora Therapeutics, Inc. quarterly revenues of --. ProKidney Corp.'s net income of -$40.9M is higher than Neumora Therapeutics, Inc.'s net income of -$56.8M. Notably, ProKidney Corp.'s price-to-earnings ratio is -- while Neumora Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProKidney Corp. is 284.65x versus -- for Neumora Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PROKProKidney Corp.284.65x -- $225K -$40.9M NMRANeumora Therapeutics, Inc.-- -- -- -$56.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
